Other News

Biobeat Demonstrates Prediction Capabilities of Its Devices in Heart Failure Patients under Diuresis

Peer-reviewed study published in Journal of Clinical Medicine validates the use of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in HF patients PETAH TIKVA, Israel, Jan. 17, 2023 /PRNewswire/ — Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, today announced the publication of clinical data demonstrating that […]

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

Dr. Irina Kulinets, seasoned U.S. and international medical device regulatory expert, joins CytoSorbents’ executive management team to lead FDA marketing approval of DrugSorb®-ATR and other global regulatory priorities PRINCETON, N.J., Jan. 17, 2023 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using […]

First Patient Enrolled in REAL SSO2 Study to Evaluate Clinical Utility and Economic Value of ZOLL TherOx SSO2 Therapy

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard of care treatment for ST-elevation myocardial infarction (STEMI) patients. The […]

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

— Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) — — Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm — — Favorable safety and tolerability — — Data support advancement of fixed-dose combination into bioequivalence and Phase 3 […]

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 14, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr. Mingdong Zhang to the company’s Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical’s clinical development and registration strategyand supporting the company’s global development plan. Pulnovo Medical is a medical device company […]

Pie Medical Imaging announces the global release of its latest echocardiography software technology, CAAS Qardia 2.0

MAASTRICHT, Netherlands, Jan. 13, 2023 /PRNewswire/ — Pie Medical Imaging (“PMI”), a global leader in cardiac imaging, today launched CAAS Qardia 2.0, a new version of their innovative echocardiography software platform. CAAS Qardia leverages artificial intelligence driven workflows for performing key clinical measurements and ease-of-access. The CAAS Qardia platform offers in-hospital deployment as so-called zero-footprint solution, meaning access from any PC within the […]

Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis

IRVINE, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that the first patient has been enrolled in DEFIANCE, a prospective randomized controlled […]

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

Triglyceride-rich LDL particles were found to be directly causal in ASCAD based on Aitia’s Digital Twins built on G3’s Global Multi-omic Clinical Study Data and Aitia’s Causal AI Technology LDL-Triglycerides may become an important diagnostic biomarker in ASCAD and may lead to new therapeutics ATLANTA and SOMERVILLE, Mass., Jan. 12, 2023 /PRNewswire/ — G3 […]

HVR CARDIO CLOSES ON $11 Million SERIES B FINANCING WITH FINLAND’S INNOVESTOR LIFE SCIENCE FUND AND TESI

HVR Cardio Announces New Leadership Team With Hiring Of CTO Tim Girton, CEO Tom Fleming HELSINKI, Finland and MINNEAPOLIS, Jan. 12, 2023 /PRNewswire/ — HVR Cardio, a clinical stage medical technology company developing Structural Heart cardiovascular products for transcatheter mitral valve repair, announced today that it has closed on its 10.7 million Euro ($11.1M US) Series B Round of financing. […]